# US 2026/0242881 A1 · Methylation signatures of pathogen and chemical exposures in human cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242881 A1
- Document ID: US20260242881A1
- Status: Published application
- Kind: A1
- Application number: 19/164,167
- Filed: 2024-03-11
- Published: 2026-08-20
- Earliest claimed: 2023-03-10
- Assignees: The Salk Institute for Biological Studies
- Applicants: Salk Institute for Biological Studies
- Inventors: Wenliang Wang; Manoj Hariharan; Joseph R. Ecker
- Web page: https://patentgrep.com/patent/US20260242881A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/703: {Viruses associated with AIDS}
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/65: Tetracyclines
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/48: involving transferase
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/689: for bacteria
- C12Q 1/701: {Specific hybridization probes}
- C12Y 207/07: Nucleotidyltransferases (2.7.7)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

Methods are provided for determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, human immunodeficiency virus type 1 (HIV-1), methicillin-susceptible Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP). Such methods include determining the measuring methylation status of numerous differentially methylated regions (DMRs) in the genomic DNA of particular PBMCs, such as those provided in Table 1, and in some examples also determining an amount of accessible chromatin in the isolated immune cells. Also provided are nucleic acid probes, arrays, solid supports (such a chip or nanosphere) and kits that can be used with such methods.

## Claims

### Claim 1

A method of determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, human immunodeficiency virus type 1 (HIV-1), influenza A, methicillin-resistant Staphylococcus aureus (MSSA), or methicillin-resistant Staphylococcus aureus (MRSA), or has been exposed to an organophosphate (OP), comprising:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, at least 1000, at least 5000, at least 5400, or all differentially methylated regions (DMRs) in genomic DNA of isolated immune cells obtained from the subject, wherein the immune cells and DMRs are provided in Table 1;
optionally determining an amount of accessible chromatin in the isolated immune cells; and
determining whether the subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, HIV-1, influenza A, MSSA, or MRSA, or has been exposed to an organophosphate (OP), based on the measured methylation status of the DMRs and the amount of accessible chromatin.

### Claim 2 (depends on 1)

The method of claim 1, further comprising treating genomic DNA of the isolated immune cells with bisulfite to convert unmethylated cytosines of CpG dinucleotides to uracil, treating genomic DNA of the isolated immune cells with a transposase to generate fragments of the genomic DNA, or both.

### Claim 3 (depends on 1)

The method of claim 1, wherein determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, HIV-1, influenza A, MSSA, or MRSA, or has been exposed to an OP, comprises applying a statistical prediction algorithm to the determined methylation status, the amount of accessible chromatin, or both.

### Claim 4 (depends on 3)

The method of claim 3, wherein applying the statistical prediction algorithm comprises (a) obtaining a linear combination of the methylation marker status of the at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, at least 1000, at least 5000, at least 5400, or all DMRs, and (b) applying a transformation to the linear combination to determining whether a subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, HIV-1, influenza A, MSSA, or MRSA, or has been exposed to an OP.

### Claim 5 (depends on 1)

The method of claim 1, wherein the isolated immune cells comprise memory B cells, naive B cells, active natural killer cells, naive natural killer cells, memory cytotoxic T cells, naive cytotoxic T cells, memory T cells, naïve T cell, and monocytes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method determines whether the subject has been exposed to or is infected with Bacillus anthracis, and determining methylation status comprises:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in B memory cells in Table 1 listed as BA B-Mem;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve B cells in Table 1 listed as BA B-Naive;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in monocytes in Table 1 listed as BA monocyte;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in active natural killer cells in Table1 listed as BA NK-cell1;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive natural killer cells in Table 1 listed as BA NK-cell2;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory cytotoxic T cells in Table 1 listed as BA Tc-mem;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive cytotoxic T cells in Table 1 listed as BA Tc-naive;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory T cells in Table 1 listed as BA Th-mem; and/or
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve T cells in Table 1 listed as BA Th-naive,
wherein detection of the DMRs in Table 1 (for BA exposure) indicates that the subject has been exposed to or is infected with Bacillus anthracis.

### Claim 7 (depends on 5)

The method of claim 5, further comprising administering to the subject a therapeutically effective amount of one or more of ciprofloxacin, doxycycline, quinolone, and penicillin, when it is indicated that the subject has been exposed to or is infected with Bacillus anthracis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method determines whether the subject has been exposed to or is infected with SARS-CoV-2, and determining methylation status comprises:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in B memory cells in Table 1 listed as COVID B-Mem;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve B cells in Table 1 listed as COVID B-Naive;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in monocytes in Table 1 listed as COVID monocyte;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in active natural killer cells in Table1 listed as COVID NK-cell1;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive natural killer cells in Table 1 listed as COVID NK-cell2;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory cytotoxic T cells in Table 1 listed as COVID Tc-mem;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive cytotoxic T cells in Table 1 listed as COVID Tc-naive;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory T cells in Table 1 listed as COVID Th-mem; and/or
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve T cells in Table 1 listed as COVID Th-naive,
wherein detection of the DMRs in Table 1 (for COVID exposure) indicates that the subject has been exposed to or is infected with SARS-CoV-2.

### Claim 9 (depends on 8)

The method of claim 8, further comprising administering to the subject a therapeutically effective amount of one or more of Paxlovid, molnupiravir, remdesivir, baricitinib and tocilizumab, when it is indicated that the subject has been exposed to or is infected with SARS-CoV-2.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method determines whether the subject has been exposed to or is infected with influenza A, and determining methylation status comprises:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in B memory cells in Table 1 listed as Flu B-Mem;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve B cells in Table 1 listed as Flu B-Naive;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in monocytes in Table 1 listed as Flu monocyte;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in active natural killer cells in Table1 listed as Flu NK-cell1;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive natural killer cells in Table 1 listed as Flu NK-cell2;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory cytotoxic T cells in Table 1 listed as Flu Tc-mem;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive cytotoxic T cells in Table 1 listed as Flu Tc-naive;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory T cells in Table 1 listed as Flu Th-mem; and/or
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve T cells in Table 1 listed as Flu Th-naive,
wherein detection of the DMRs in Table 1 (for Flu exposure) indicates that the subject has been exposed to or is infected with influenza A.

### Claim 11 (depends on 10)

The method of claim 10, further comprising administering to the subject a therapeutically effective amount of one or more of oseltamivir, zanamivir, and peramivir, when it is indicated that the subject has been exposed to or is infected with influenza A.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method determines whether the subject has been exposed to or is infected with HIV-1, and determining methylation status comprises:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in B memory cells in Table 1 listed as HIV B-Mem;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve B cells in Table 1 listed as HIV B-Naive;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in monocytes in Table 1 listed as HIV monocyte;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in active natural killer cells in Table1 listed as HIV NK-cell1;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive natural killer cells in Table 1 listed as HIV NK-cell2;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory cytotoxic T cells in Table 1 listed as HIV Tc-mem;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive cytotoxic T cells in Table 1 listed as HIV Tc-naive;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory T cells in Table 1 listed as HIV Th-mem; and/or
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naïve T cells in Table 1 listed as HIV Th-naive,
wherein detection of the DMRs in Table 1 (for HIV exposure) indicates that the subject has been exposed to or is infected with HIV-1.

### Claim 13 (depends on 12)

The method of claim 12, further comprising administering to the subject a therapeutically effective amount of a highly active antiretroviral therapy (HAART), when it is indicated that the subject has been exposed to or is infected with HIV-1.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method determines whether the subject has been exposed to or is infected with MSSA or MRSA, and determining methylation status comprises:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in B memory cells in Table 1 listed as MRSA B-Mem;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive B cells in Table 1 listed as MRSA B-Naive;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in monocytes in Table 1 listed as MRSA monocyte;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in active natural killer cells in Table1 listed as MRSA NK-cell1;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive natural killer cells in Table 1 listed as MRSA NK-cell2;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory cytotoxic T cells in Table 1 listed as MRSA Tc-mem;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive cytotoxic T cells in Table 1 listed as MRSA Tc-naive;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory T cells in Table 1 listed as MRSA Th-mem; and/or
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive T cells in Table 1 listed as MRSA Th-naive,
wherein detection of the DMRs in Table 1 (for MRSA exposure) indicates that the subject has been exposed to or is infected with MSSA or MRSA.

### Claim 15 (depends on 13)

The method of claim 13, further comprising administering to the subject a therapeutically effective amount of one or more of vancomycin, ceftaroline, teicoplanin, clindamycin, and linezolid, when it is indicated that the subject has been exposed to or is infected with MRSA, or further comprising administering to the subject a therapeutically effective amount of one or more of a beta-lactam antibiotic (such as penicillin and its derivatives (such as methicillin and oxacillin) and cephems such as the cephalosporins), flucloxacillin, and a triple antibiotic ointment, when it is indicated that the subject has been exposed to or is infected with MSSA.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method determines whether the subject has been exposed to one or more OPs, and determining methylation status comprises:
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in B memory cells in Table 1 listed as OP B-Mem;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive B cells in Table 1 listed as OP B-Naive;
determining methylation status of at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in monocytes in Table 1 listed as OP monocyte;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in active natural killer cells in Table1 listed as OP NK-cell1;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive natural killer cells in Table 1 listed as OP NK-cell2;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory cytotoxic T cells in Table 1 listed as OP Tc-mem;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive cytotoxic T cells in Table 1 listed as OP Tc-naive;
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in memory T cells in Table 1 listed as OP Th-mem; and/or
determining methylation status of at least at least 20, at least 25, at least 30, at least 40, at least 50, or at least 100 of the DMRs in naive T cells in Table 1 listed as OP Th-naive,
wherein detection of the DMRs in Table 1 (for OP exposure) indicates that the subject has been exposed to one or more OPs.

### Claim 17 (depends on 16)

The method of claim 16, further comprising administering to the subject a therapeutically effective amount of one or more of carbamate, anti-cholinergic drugs (e.g., atropine, oximes (such as pralidoxime, and diazepam)); cholinesterases (ChEs), such as human serum BChE (HuBChE); and class II anti-arrhythimic agents, when it is indicated that the subject has been exposed to one or more organophosphates (OPs).

### Claim 18 (depends on 1)

The method of claim 1, wherein isolated immune cells are obtained from a blood sample.

### Claim 19 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 20 (depends on 1)

The method of claim 1, wherein determining the methylation status or determining an amount of accessible chromatin comprises hybridizing the genomic DNA to polynucleotides attached to a solid support.

### Claim 21 (depends on 20)

The method of claim 20, wherein the polynucleotides attached to a solid support comprise at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, at least 1000, at least 5000, or at least 5400 of the differentially methylated regions in Table 1.

### Claim 22 (depends on 1)

The method of claim 1, further comprising obtaining the isolated immune cells from the subject.

### Claim 23 (depends on 1)

The method of claim 1, further comprising extracting genomic DNA from the isolated immune cells.

### Claim 24 (depends on 1)

The method of claim 1, further comprising selecting the subject, wherein the subject has been or is suspected of having been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, HIV-1, or MSSA, MRSA, or exposed to an OP.

### Claim 25 (depends on 1)

The method of claim 1, further comprising reporting whether the subject has been exposed to or infected with Bacillus anthracis, SARS-CoV-2, influenza A, HIV-1, or MSSA, MRSA, or exposed to an OP.

### Claim 26 (depends on 25)

The method of claim 25, wherein the reporting comprises preparing a written or electronic report.

### Claim 27

A kit, comprising:
nucleic acid probes and/or primers for detecting at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 500, at least 1000, at least 5000, or at least 5400 of the differentially methylated regions in Table 1,
optionally nucleic acid probes and/or primers for determining an amount of accessible chromatin in human immune cells, and
optionally sodium bisulfite, transposase, or both.
